SARS-CoV-2疫苗接种在吉兰-巴雷综合征、慢性炎性脱髓鞘性多发性神经根神经病和多灶性运动神经病中的安全性
这项前瞻性多中心队列研究纳入521例有吉兰-巴雷综合征(GBS)、慢性炎性脱髓鞘性多发性神经根神经病(CIDP)或多灶性运动神经病(MMN)病史的患者,评估SARS-CoV-2疫苗接种后GBS复发及CIDP或MMN症状加重的风险。162例GBS患者接种后无复发;188例CIDP患者中10例(5%)报告症状加重,5例(3%)调整维持治疗;53例MMN患者中2例(4%)报告症状加重,1例调整治疗。作者认为接种后GBS复发风险未增加,CIDP或MMN相关症状加重风险低至可忽略。
要点
- 162例GBS患者接种SARS-CoV-2疫苗后无复发。
- 188例CIDP患者中10例(5%)接种后6周内症状加重,5例(3%)调整维持治疗。
- 53例MMN患者中2例(4%)症状加重,1例调整治疗。
核心结论
- 作者认为SARS-CoV-2疫苗接种后GBS复发风险未增加,CIDP或MMN相关症状加重风险低至可忽略,在这些免疫介导性神经病患者中接种似乎安全。
研究设计与样本
- 前瞻性多中心队列研究,2021年1月至2021年8月开展。
- 邀请3家荷兰大学医学中心(以免疫介导性神经病为研究重点)已知患者及荷兰神经肌肉疾病患者协会成员参与,条件为18岁及以上且诊断为GBS、CIDP或MMN。
- 向1152人发送问卷,674人(59%)签署知情同意,排除153人(多数因研究基线前已接种SARS-CoV-2疫苗或已感染,占84%),最终521人纳入分析,403人(81%)完成最后一次问卷(时间点4)。
主要发现
- 162例有GBS病史的参与者接种后无复发。
- 188例CIDP患者中10例(5%)报告接种后6周内症状加重,其中5例(3%)调整维持治疗。
- 53例MMN患者中2例(4%)报告症状加重,1例报告治疗调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: There are concerns on the safety of SARS-CoV-2 vaccination in patients with a history of Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). The aim of this study was to determine the risk of recurrence of GBS and exacerbations of CIDP or MMN after SARS-CoV-2 vaccination. METHODS: We conducted a prospective, multicenter cohort study from January 2021 to August 2021. Patients known in 1 of 3 Dutch University Medical Centers with research focus on immune-mediated neuropathy and members of the Dutch Patient Association for Neuromuscular Diseases were invited to participate if they were 18 years or older and diagnosed with GBS, CIDP, or MMN. Participants completed a series of questionnaires at 4 different time points: study baseline (1), within 48 hours before any SARS-CoV-2 vaccination (2 and 3, if applicable), and 6 weeks after their last vaccination (4). Participants unwilling to get vaccinated completed the last questionnaire (4) 4 months after study baseline. We assessed recurrences of GBS, any worsening of CIDP or MMN-related symptoms, treatment alterations, and hospitalization. RESULTS: Of 1,152 individuals to whom we sent the questionnaires, 674 (59%) signed informed consent. We excluded 153 individuals, most often because they had already received a SARS-CoV-2 vaccination or had had the infection (84%) before study baseline. Of 521 participants included in analyses, 403 (81%) completed the last questionnaire (time point 4). None of 162 participants with a history of GBS had a recurrence after vaccination. Of 188 participants with CIDP, 10 participants (5%) reported a worsening of symptoms within 6 weeks after vaccination. In 5 (3%) of these patients, maintenance treatment was modified. Two of 53 participants with MMN (4%) reported a worsening of symptoms, and treatment modification was reported by 1 participant. DISCUSSION: We found no increased risk of GBS recurrence and a low to negligible risk of worsening of CIDP or MMN-related symptoms after SARS-CoV-2 vaccination. Based on our data, SARS-CoV-2 vaccination in patients with these immune-mediated neuropathies seems to be safe.
引用
- Baars AE, Kuitwaard K, de Koning LC, et al. SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy. Neurology. 2022. PMID: 36127144. doi:10.1212/WNL.0000000000201376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。